CordenPharma Invests >€1 billion to Expand its Greenfield Facility
Introduction:
CordenPharma has announced plans to invest more than €1 billion over the next three years to build and expand peptide manufacturing facilities across Europe and the United States. This initiative is aimed at strengthening its capabilities in small, medium, and large-scale peptide production.
Features:
A highly efficient infrastructure with well-established systems for material handling and process management, essential for advanced peptide manufacturing.
Seamless logistics with direct access to major transportation networks for efficient supply chain operations.
Existing large-scale utilities designed to meet the demands of chemical manufacturing.
Proximity to Basel—a leading pharma and biotech hub at the intersection of Germany, France, and Switzerland—offering access to a highly skilled workforce.
Integration within a thriving industrial park that promotes sustainable operations through closed-loop energy and material cycles, innovative waste-to-value initiatives, and a strategic roadmap toward achieving net-zero emissions.
The expansion is completed by 2028.
Specifications:
Name : CordenPharma
Type : Expansion
Budget : >€1 Billion
Year : 2028
